Compound class

Healing peptides

Short peptides, listed with what FDA documents say about human data.

Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.

Most compounds here are short peptides: TB-500 is a seven-amino-acid fragment of thymosin beta-4,1 thymosin alpha-1 has 28 amino acids,2 and KPV is a tripeptide.3 FDA's briefing documents found no human pharmacokinetic data for BPC-157 after oral, subcutaneous, nasal or transdermal use; in two rectal enema studies that measured plasma levels, BPC-157 was reported as not detected, or mostly below the lower limit of quantification.4 The same documents found no human pharmacokinetic or pharmacodynamic studies of TB-500,1 and no clinical studies of KPV in humans.3 Thymosin alpha-1 differs, as the same FDA document calls Zadaxin a finished drug product available in other countries.2

Compounds in this class 17

Half-lives side by side

The figure each source gives, on one scale. Bars are ranges.

  • ARA-290 (Cibinetide)about 2 min, review
  • Glutathione14.1 min, IV
  • Thymosin Alpha-1about 2 h

Log scale, 1 minute to about 3 weeks. Each figure and its source are in the list above. Minutes, days and weeks are turned into hours (1 day is 24 hours) only to place them on the scale. These are the sources' figures; the half-life the app uses to draw levels can differ.

Where some figures in the list come from

  • Glutathione: Tationil, the Italian injection behind its status, is labelled for preventing nerve damage from chemotherapy with cisplatin or similar drugs.5

Guides 15

Calculators 11

Logged in Milligram

Share of people who logged a dose in Milligram in the 90 days to 15 November 2026 who logged each compound.

  • KLOW9%
  • BPC-157 + TB-5007%
  • BPC-1576%
  • Glutathione3%
  • KPV3%

KLOW, how often

  • Daily69%
  • Every other day20%
  • Twice a week7%
  • Weekly3%
  • Less often1%

BPC-157 + TB-500, how often

  • Daily60%
  • Every other day24%
  • Twice a week11%
  • Weekly3%
  • Less often1%

BPC-157, how often

  • Daily75%
  • Every other day18%
  • Twice a week5%
  • Weekly2%
  • Less often0%

Glutathione, how often

  • Daily20%
  • Every other day46%
  • Twice a week23%
  • Weekly9%
  • Less often1%

KPV, how often

  • Daily68%
  • Every other day29%
  • Twice a week3%
  • Weekly0%
  • Less often0%

How often: among people with three or more logged doses, by the average gap between their doses.

Aggregated and anonymous, shares of people only. Each compound not listed: too few people logged it to show a share. It describes what people set up in the app, not advice on what to take.

References 14

  1. Mathew B, Mattingly A, Rupp T, Albuquerque E, Benedict A, Kneeream E, Kasim S (US Food and Drug Administration). July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). FDA 2026. fda.gov
  2. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: thymosin alpha-1-related bulk drug substances. 2024. fda.gov
  3. US Food and Drug Administration. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee: FDA Briefing Document for KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate). 2026. fda.gov
  4. US Food and Drug Administration. FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting July 23 - 24, 2026. 2026. fda.gov
  5. Teofarma. Tationil (glutathione) 600 mg powder and solvent for solution for injection. Italian summary of product characteristics (riassunto delle caratteristiche del prodotto), text revised June 2010. Tationil product information
  6. Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest 1991. PMID 1907548
  7. Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol 2025. PMID 39444151
  8. Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther 2015. PMID 25728128
  9. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015. PMID 25387363
  10. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012. PMID 23168581
  11. Miranda E, Bramono K, Yunir E, et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res 2023. PMC10514151
  12. Domschke S, et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 1978;19(11):1049-53. PMID 730072
  13. ClinicalTrials.gov. NCT04536350: Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS. NCT04536350
  14. Invicorp 25 micrograms/2 mg solution for injection (aviptadil and phentolamine mesilate). Evolan Pharma AB. Swedish summary of product characteristics (produktresumé), revised 2026. Invicorp product information

Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.